Aphios

Inspired by Nature, Enabled by Science®
Leading the way in developing green, enabling biotechnology and nanotechnology drug delivery platforms.

[Aphios @Aphios]

🧠 Epilepsy affects 50–60M globally, incl. 3M adults & 500K kids in the US.
⚠️ 30% have drug-resistant epilepsy.
Join Aphios Pharma Nov 18 @ 4:30 PM EST for a webinar on extended-release cannabinoid nanoparticles.
🔗 https://t.co/eEh78PN610
#Epilepsy #CBD #Refractory #Chronic #Cannabinoid #Nanoparticles #ExtendedRelease

[Aphios @Aphios]

🧠 Epilepsy affects 50–60M globally, incl. 3M adults & 500K kids in the US.
⚠️ 30% have drug-resistant epilepsy.
Join Aphios Pharma Nov 18 @ 4:30 PM EST for a webinar on extended-release cannabinoid nanoparticles.
🔗 https://t.co/eEh78PMybs
#Epilepsy #CBD #Refractory #Chronic #Cannabinoid #Nanoparticles #ExtendedRelease

[Aphios @Aphios]

Next week, I will present “Utilizing Nanoencapsulated Cannabinoid Therapies for Treating Chronic Opioid Use Disorder” at the 8thAnnual Cannabinoid & Endocannabinoid Drug Development Summit being held in Boston, MA from October 15-16, 2025. Join us in this exciting event! @trevorcastor

[Aphios @Aphios]

Next week, I will present “Utilizing Nanoencapsulated Cannabinoid Therapies for Treating Chronic Opioid Use Disorder” at the 8thAnnual Cannabinoid & Endocannabinoid Drug Development Summit being held in Boston, MA from October 15-16, 2025. Join us in this exciting event!

[Aphios @Aphios]

@trevorcastor Closing soon in one day! Aphios Pharma LLC is developing next generation, extended-release cannabinoid nanoparticles for chronic Addiction, Anxiety, Pain, Multiple Sclerosis and Epilepsy. Join us on our journey! https://t.co/gQlreFvjGD

[Aphios @Aphios]

Closing soon in one day! Aphios Pharma LLC is developing next generation, extended-release cannabinoid nanoparticles for chronic Addiction, Anxiety, Pain, Multiple Sclerosis and Epilepsy. Join us on our journey! https://t.co/gQlreFvRwb

[Aphios @Aphios]

Closing soon in two days! Aphios Pharma LLC is developing next generation, extended-release cannabinoid nanoparticles for chronic Addiction, Anxiety, Pain, Multiple Sclerosis and Epilepsy. Join us on our journey! https://t.co/gQlreFvRwb #Anxiety #Addiction #Pain #MS #Epilepsy

[Aphios @Aphios]

🚨 Big news from @AphiosPharma!
Our CEO Dr. Trevor Castor will present at #ACS2025 on breakthrough extended-release cannabinoid nanoparticles for pain, anxiety, addiction & CNS disorders. 🌿💊
Science that lasts. Relief that matters.
#CannabinoidTherapy #Biotech #PainRelief

[Aphios @Aphios]

🚨 Big news from @AphiosPharma!
Our CEO Dr. Trevor Castor will present at #ACS2025 on breakthrough extended-release cannabinoid nanoparticles for pain, anxiety, addiction & CNS disorders. 🌿💊
Science that lasts. Relief that matters.
#CannabinoidTherapy #Biotech #PainRelief

[Aphios @Aphios]

Anxiety is our instinctive response to stress, developed through evolution to protect humankind. We are empowering patients to treat chronic CNS disorders. Join us on our journey! https://t.co/gQlreFvRwb #Anxiety #Addiction #Pain #MS #Epilepsy

[Aphios @Aphios]

We are developing #cannabinoid #nanoparticles to treat chronic #pain that impacts more than 100 million Americans. Join us on our journey to develop and deliver this therapy to patients in need of sustained relief. https://t.co/LEoLslKwI7 #Addiction #Anxiety #MS #Epilepsy

[Aphios @Aphios]

Aphios granted US Patent No. 11,981,174 for a novel process converting CBDA to CBD and other acid cannabinoids. This cGMP-compliant method improves efficiency, quality, and cost for pharmaceutical-grade cannabinoids. 🌿💊 #CBD #Innovation #CannabisTech https://t.co/WgR5ifSUC9

[Aphios @Aphios]

Aphios granted US Patent No. 11,981,174 for a novel process converting CBDA to CBD and other acid cannabinoids. This cGMP-compliant method improves efficiency, quality, and cost for pharmaceutical-grade cannabinoids. 🌿💊#CBD #Innovation #CannabisTech https://t.co/WgR5ifSUC9

[Aphios @Aphios]

Anxiety disorders are rapidly emerging as a critical public health concern, affecting nearly 1 in 5 American adults and 1 in 3 adolescents annually. We are developing cannabis-based, FDA-approved drugs for #Anxiety https://t.co/LEoLslKwI7 #Pain #MultipleSclerosis #Epilpesy

[Aphios @Aphios]

110 million Americans suffer from lower back #pain and more than 50% of cancer patients suffer from chemotherapy induced pain. Aphios Pharma is developing cannabis-based, FDA-approved drugs for pain. https://t.co/LEoLslJYSz #Addiction, #Anxiety, #MultipleSclerosis, #Epilpesy

[Aphios @Aphios]

Many cancer patients suffer from chemotherapy induced peripheral neuropathic pain (CIPNP) for which there are no effective solutions except opioids. Join us on our mission to develop an effective therapeutic for cancer pain. https://t.co/LEoLslKwI7 #Addiction, #Anxiety, #Pain

[Aphios @Aphios]

Our journey to develop natural therapeutics for chronic ailments through innovative cannabinoid nanoparticle technology is in full swing with strong support. Join us on our mission. #Addiction, #Anxiety, #Pain, #MultipleSclerosis, #Epilpesy https://t.co/LEoLslKwI7

[Aphios @Aphios]

Join our mission to harness the power of cannabinoid nanoparticles to rebalance the natural endocannabinoid system, which plays a crucial role in managing debilitating diseases. #Addiction #Anxiety #Pain #Cannabinoids #Nanoparticles #MS #Epilepsy https://t.co/LEoLslKwI7

[Aphios @Aphios]

We are developing an anti-CCR5 antagonist shuttled across the blood brain barrier in targeted nanoparticles to treat brain inflammation and Alzheimer’s disease by knocking down the CCR5 gene https://t.co/MEXQTCXpje #Alzheimer, #Dementia, #Inflammation, #CCR5, #Nanoparticles